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ABSTRACT
Clefts of the palate and/or lip are among the most common human
craniofacial malformations and involve multiple genetic and
environmental factors. Defects can only be corrected surgically and
require complex life-long treatments. Our studies utilized the well-
characterized Pax9−/− mouse model with a consistent cleft palate
phenotype to test small-molecule Wnt agonist therapies. We show that
the absence of Pax9 alters the expression of Wnt pathway genes
including Dkk1 and Dkk2, proven antagonists of Wnt signaling. The
functional interactions betweenPax9 andDkk1 are shown by the genetic
rescue of secondary palate clefts in Pax9−/−Dkk1f/+;Wnt1Cre embryos.
The controlled intravenous delivery of small-molecule Wnt agonists (Dkk
inhibitors) into pregnant Pax9+/− mice restored Wnt signaling and led to
the growth and fusion of palatal shelves, asmarked by an increase in cell
proliferation and osteogenesis in utero, while other organ defects were
not corrected. This work underscores the importance of Pax9-dependent
Wnt signaling in palatogenesis and suggests that this functional
upstream molecular relationship can be exploited for the development
of therapies for human cleft palates that arise from single-gene disorders.
KEY WORDS: Pax9, Wnt, Palatogenesis, Cleft palate, Mouse, Wnt
agonist, Small molecule
INTRODUCTION
Failures in palatogenesis occur during the outgrowth, elevation,
migration and fusion of palatal shelves, providing the best evidence
that these developmental processes are under strict molecular
control (Mossey et al., 2009; Greene and Pisano, 2010). Since the
sequence of events in murine palatogenesis closely resembles that
seen in humans, mouse genetic models with secondary palate
defects have been valuable in dissecting the signaling pathways that
drive palatogenesis (Funato et al., 2015). Gene ontology reveals that
more than half of the genes associated with palatal clefts in mice are
transcription factors, including Msx1 (Satokata and Maas, 1994;
Zhang et al., 2002), Pax9 (Peters et al., 1998; Zhou et al., 2011),
Osr2 (Lan et al., 2004), Gbx2 (Byrd and Meyers, 2005), Tbx22
(Pauws et al., 2009), Tfap2a (Brewer et al., 2004) and Hoxa2
(Gendron-Maguire et al., 1993). Moreover, growth factor families
such as TGFβ, Shh, Fgf and Wnt, along with membranous
molecules and extracellular matrix proteins are also implicated as
playing important roles in palate formation (Greene and Pisano,
2010; Funato et al., 2015). Taken together, these studies reveal that a
tight interplay of gene networks and environmental risk factors
regulates key molecular, cellular and tissue interactions during
palate development. However, much remains to be learned about
how these molecules function and how such knowledge can be
translated into new treatment strategies for preventing or reversing
cleft conditions in humans.
Among the mouse genetic models of cleft palate that are available
for study, the Pax9−/−model has provided valuable insights into the
mechanisms that lead to the failure of palatogenesis. Pax9 belongs
to the family of paired-box DNA-binding domain-containing
transcription factors, which play key roles in organogenesis
(Stapleton et al., 1993). Pax9−/− mice consistently exhibit clefts
of the secondary palate and die shortly after birth. Other phenotypic
defects include agenesis of the thymus, parathyroid glands,
ultimobranchial bodies and teeth (Peters et al., 1998; Zhou et al.,
2011). It has been proposed that Pax9 is involved in molecular
signaling events that control the patterning of the anterior-posterior
(AP) axis during palatal shelf outgrowth. Its control of cell
proliferation and its interactions with the Bmp, Fgf and Shh
pathways are hence important for expansion of the palatal shelves
and their growth along the AP axis and towards the midline (Zhou
et al., 2013). However, little is known about the morphogenetic
gradient that controls patterning of the palatal shelves along the
buccal-lingual axis. This information is crucial as the closure of
palatal shelves towards the midline relies on the precise actions and
interactions of genes along this axis.
In these studies we demonstrate the functionality of the upstream
molecular relationship of Pax9 with Wnt signaling during
palatogenesis. Our unbiased genome-wide analyses show that the
inhibitors of Wnt, namely Dkk1 and Dkk2, are significantly
upregulated in Pax9−/− palatal mesenchyme, while Wnt genes are
downregulated. Definitive evidence of the importance of the
relationship of Pax9 to Dkk1 is shown by the genetic rescue of
secondary palate clefts in mice that are deficient in both Dkk1 and
Pax9. Furthermore, the controlled intravenous delivery of a small-
molecule Wnt agonist, which specifically inhibits Dkk1, into
pregnant Pax9+/− mice corrects 100% of cleft palate defects in
mutant progeny. These studies underscore the importance of Pax9-
dependent Wnt signaling during palatogenesis and suggest that Wnt
agonist therapies can be exploited to correct cleft palate conditions
in humans that arise from single-gene defects.
RESULTS
Pax9 is upstreamof theWnt signaling pathwayduringmurine
palatogenesis
We first examined the molecular consequences of Pax9 deficiency
in palatal shelves at E13.5 by RNASeq analyses. Our data indicateReceived 29 July 2017; Accepted 5 September 2017
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that the complete lack of Pax9 led to more than a 1.5-fold
(P<0.01) change in expression of 1368 genes, among which the
Wnt pathway genes appear strongly enriched (Table 1, left
column). Significant is the higher expression of dickkopf 1
(Dkk1) and Dkk2, which encode extracellular proteins that block
the binding of Wnt ligands to the Lrp5/6 receptor complex. The
expression of Wnt ligands Wnt3, Wnt7a and Wnt9b was also
altered, along with genes involved in Bmp, ectodysplasin (Eda),
Fgf and Shh signaling (Table 1, right column). Quantitative
RT-PCR analysis (Fig. 1) confirmed that the Wnt signaling pathway
inhibitors Dkk1 and Dkk2 had increased 1.7-fold. By contrast, Lef1,
Gbx2, Hand2 and Fgf4, which are involved in Wnt signaling, and
Msx1 andMsx2, which are proved partner genes of Pax9 (Zhou et al.
2011), were significantly downregulated in the absence of Pax9.
Moreover, Tfap2b, a member of the Ap2 family that interacts with
Cited1 during craniofacial development (Bragança et al., 2002;
Knight et al., 2005), was reduced more than 2-fold in E13.5 Pax9−/−
palates.
The relationship between Pax9 and the Wnt pathway was further
assessed by studying the expression patterns of Dkk1, Dkk2 and
Pax9 during normal palatogenesis. As shown in Fig. 2A-D, Dkk1
and Dkk2 expression levels increased from E13.5 to E14.5 and
appeared restricted to posterior palatal mesenchyme, while Pax9
was expressed more strongly and present in both anterior and
posterior palatal mesenchyme (Fig. 2E,F,K,L). Dkk1 transcripts are
more visible in posterior palate compared with the anterior region
(Fig. 2G,H) but appear less abundant than those of Dkk2 and Pax9
in the posterior region of E13.5 palate (Fig. 2H,J,L). The buccal-
lingual gradient of expression for Pax9 and Dkk2 is inversely
related, with Pax9 stronger on the buccal aspects of the palatal
shelves (Fig. 2L) and Dkk2 transcripts more localized to the lingual
region (Fig. 2J). Whereas Pax9 expression is broader and occupies
the entire palatal mesenchyme in anterior palate (Fig. 2K), low
levels of Dkk1/2 expression are visible in the anterior region
(Fig. 2G,I,M,Q). Interestingly, these expression domains of Dkk1,
Dkk2 and Pax9 in posterior palatal mesenchyme differ from that of
Msx1, which localizes to the anterior region of the palatal
mesenchyme (Zhang et al., 2002; Han et al., 2009; Fuchs et al.,
2010).
In situ hybridizations showed that expression of both Wnt
inhibitors increased inPax9−/− palatal mesenchyme (Fig. 2M-T). At
E13.5, Dkk1 expression was detected in Pax9+/+ posterior palatal
mesenchyme (Fig. 2H,N), whereas its expression had increased in
the posterior palate and extended into the anterior zone of Pax9−/−
palatal mesenchyme (Fig. 2O,P). Dkk2 expression was also higher
in the posterior palatal mesenchyme, with a lingual to buccal
gradient of distribution (Fig. 2J,R) that intensified in Pax9−/−
tissues (Fig. 2T).
In order to assess whether the molecular upstream relationship
between Pax9 and the Wnt pathway was functional, we generated
compound mutant mice in which Dkk1 expression was reduced in a
Pax9-deficient background. Pax9+/−Dkk1f/+ embryos showed
normal secondary palates (Fig. 3A,D,G), whereas Pax9−/−Dkk1f/+
littermates showed clefts in this region (Fig. 3B,E,H). In all Pax9−/−
Dkk1f/+;Wnt1Cre compoundmutant mice retrieved (n=5), a complete
rescue of secondary palate clefts was noted (Fig. 3C,F,I). All five
Pax9−/−Dkk1f/+;Wnt1Cre compound mutant mice retained a
supernumerary digit (Fig. S1L) and showed significant delay in
tooth development (Fig. S1C), both features representing a consistent
phenotype of Pax9−/−Dkk1f/+ mice (Fig. S1B,K). Furthermore,
agenesis of the parathyroid glands and thymus was not rescued in
Pax9−/−Dkk1f/+;Wnt1Cre compound mutant mice (Fig. S1F,I). Four
of the five mice in this group were retrieved at E18.5 for analysis and
the remaining pup that was born did not survive postnatally.
Small-molecule Wnt agonists correct cleft palate defects
in Pax9−/− mice
The small-molecule WAY-262611, which potentiates Wnt–β-
catenin signaling by specifically inhibiting Dkk1 (Pelletier et al.,
2009), was administered daily from E10.5 to E14.5, a critical
developmental window during which palate initiation, shelf
outgrowth and elevation occur (Fig. 4). The delivery of five doses
of WAY-262611 (Fig. S2A), at either 12.5 or 25 mg/kg, into the tail
veins of pregnant Pax9+/− mice resulted in fusion of the secondary
palate in all Pax9−/− pups examined (n=18). Treatment from E10.5
to E13.5 rescued the cleft phenotype, but to a lesser extent than
observed with the E10.5 to E14.5 regimen (Table 2). As shown in
Table 2, 60% (11/18) additionally displayed complete fusion
between the primary and secondary palates, while 7/18 showed
minor residual defects in the zone of fusion of the primary and
secondary palates around the third ruga (Fig. 2B). SincePax9−/− pups
die shortly after birth, E18.5 palatal shelves with residual defects were
obtained from the group treated with WAY-262611 and cultured for
3 days. As shown in Fig. S3, all palates displayed complete fusion of
residual defects. This suggests that the lack of complete fusion was
due to a timing delay rather than to any differences in gene expression
between the primary and secondary palates.
Recent studies (Li et al., 2017) showed partial rescue of palatal
defects in 64% of Pax9−/− embryos treated from E12.5 to E14.5
using an intraperitoneal route of delivery of another small-molecule
Wnt agonist, IIIc3a. IIIc3a blocks the Wnt antagonists Dkk1, Dkk2
and Dkk4 (Li et al., 2012). Here, we tested the effects of daily
Table 1. Expression profiles of Pax9-affected genes with functional enrichment analysis in E13.5 palatal shelves
Gene Pax9+/− Pax9−/− FC P-value Gene Pax9+/− Pax9−/− FC P-value
Dkk1 180.64 324.53 1.80 3.88E-03 Tfap2b 2405.06 873.21 −2.75 3.22E-85
Dkk2 3199.37 4888.36 1.52 8.71E-13 Msx1 6554.76 3221.79 −2.03 2.22E-41
Wnt7a 25.82 6.91 −3.74 0.005 Msx2 477.41 265.37 −1.80 4.58E-04
Wnt3 42.53 20.30 −2.09 5.58E-03 Bmp4 1522.38 867.67 −1.75 2.82E-16
Wnt9b 65.42 35.74 −1.83 3.34E-03 Osr2* 11254.15 6338.19 −1.72 7.98E-24
Lef1 1231.91 600.32 −2.05 1.02E-16 Foxf1 5657.10 3784.74 −1.50 3.81E-10
Rspo1 982.53 631.61 −1.56 8.00E-03 Hand2 165.14 63.62 −2.59 1.06E-10
Gbx2 26.34 6.24 −4.22 4.29E-05 Cited1 404.22 165.68 −2.44 1.28E-07
Gad1 32.42 4.53 −7.16 6.87E-14 Ret 550.22 149.65 −3.68 1.99E-22
Fgf4 109.69 9.22 −11.90 2.93E-05 Hoxa2 28.37 2.77 −10.24 3.39E-03
Edar 184.38 98.87 −1.86 3.41E-05 Ryr1 876.49 2062.90 2.35 7.30E-03
Expression levels are shown as normalized counts. FC, fold change; −, downregulation. *Normalized counts using reads from endogenous Osr2.
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intravenous delivery of IIIc3a to pregnant dams from E10.5 to
E14.5. This schedule of IIIc3a intervention resulted in closure of the
secondary palate defects in 80% (12/15) of embryos, of which six
embryos showed residual fusion defects (Table 2). The sample size
for each treatment group was confirmed by power analysis (using
PASS version 11, NCSS; provided by University of Utah Study
Design and Biostatistics Center) to reach power >80%.
H&E as well as Masson’s trichrome staining revealed that both
pharmacological interventions brought about a true correction of the
secondary palatal defect and the deposition of collagen-enriched
matrix in the area of the midline (Fig. 5A-P). The more detailed
analyses of the molecular mechanisms underlying the correction of
palatal defects was performed on tissues exposed to WAY-262611
treatment, as successful outcomes reached 100% with this
experimental group.
Since Pax9 regulatesMsx1, a transcription factor that also plays a
role in palatogenesis, intravenous injections of WAY-262611 and
IIIc3a at 25 mg/kg were given to pregnant Msx1+/− mice. Such
interventions failed to rescue cleft palate defects in mutant pups
(0/50; Fig. S4). Since Msx1 expression is spatially restricted to the
anterior region of palatal mesenchyme, where Dkk1 and Dkk2 are
expressed at low levels, it is likely that the reactivation of Wnt
signaling only influenced downstream events in posterior regions of
the palate where Pax9 is more dominantly expressed.
The in utero delivery of Wnt agonists restores growth of the
palatal shelves
Evidence that these pharmacological interventions activated Wnt
signaling in palatal mesenchyme comes from the increased levels of
β-catenin (Ctnnb1) activity visible in Pax9−/− palatal mesenchyme
after treatment with WAY-262611 or IIIc3a (Fig. 6A-F). RNASeq
data showed increased levels of Wnt target gene expression in
treated palates (Table 3). WAY-262611 had no effect on Dkk1 and
Fig. 1. Quantitative RT-PCR analysis of gene expression in E13.5 Pax9−/−
palatal shelves. The mRNA levels of a select group of differentially expressed
genes were verified in microdissected palatal shelves of Pax9+/+ and Pax9−/−
mouse embryos by quantitative RT-PCR (n=5 per group). Pax9 deficiency
affects the expression of Wnt signaling pathway genes and known partner
genes of Pax9. The expression levels of Dkk1 and Dkk2 are significantly
upregulated in the absence of Pax9. By contrast, Wnt signaling pathway
downstream targets, such as Lef1,Gbx2, Fgf4 andHand2, as well as the Pax9
partner genes Msx1 and Msx2, were significantly downregulated in Pax9−/−
samples. Results are shown as percentage of the mean±s.e.m. of the Pax9+/+
group. *P<0.01.
Fig. 2. Patterns of Pax9, Dkk1 and Dkk2 expression in
E13.5 Pax9+/− and Pax9−/− palatal shelves suggest that
Pax9 is upstream of Wnt signaling. (A,B) Whole-mount
lacZ staining (blue) showing that Dkk1 expression is
restricted to the posterior domain of palatal shelves in
Dkk1Tg107−lacZ embryos at E13.5 and E14.5. Red dashed
lines indicate the boundary of palate. (C,D) Whole-mount
in situ hybridization with digoxigenin-labeled probes
showing that Dkk2 transcripts (purple) are more visible at
themedial edges of the palatal shelves inPax9+/+ embryos
at E13.5 and E14.5. (E,F) By contrast, Pax9 expression
appears stronger and expands along the AP domain of
palatal shelves at E13.5 and E14.5. Black dashed lines
indicate the position of the sections in G-L. (G-L) In situ
hybridizations on adjacent sections, presented in the
coronal plane, confirm that Dkk1 (G,H) and Dkk2 (I,J)
transcripts have inverse expression patterns with that of
Pax9 (K,L) at E13.5 and E14.5. Pax9 expression is
more intense along the buccal aspects of palatal
mesenchyme (K,L), whereas Dkk2 transcripts localize on
the lingual side (I,J). Arrows indicate the higher expression
domain. (M-T) In the posterior regions of palatal
mesenchyme, Dkk1 (M-P) and Dkk2 (Q-T) expression
increased at E13.5 as a result of Pax9 deficiency. B,
buccal; L, lingual; T, tongue. n=6 for whole-mount in situ
hybridization, n=5 for section in situ hybridization.
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Dkk2 mRNA levels as it acts at the protein level. Expression levels
of Gbx2 and L1cam, which are downstream targets of Wnt
signaling, are restored following Wnt agonist therapy (Fig. 6G).
Notably, Gbx2 mutant mice have cleft palate defects, while L1cam-
deficient mice show other craniofacial defects (Byrd and Meyers,
2005). Furthermore, quantitative RT-PCR analysis showed that the
expression levels of endogenous Osr2, Msx1 and Bmp4, which
were significantly downregulated in the absence of Pax9, were
not restored after treatment with WAY-262611 (Fig. S5). This
suggested that the signaling hierarchy involving Pax9 and the Wnt
pathway, although crucial in posterior palatal mesenchyme, might
not involve these molecules.
As detailed by Zhou et al. (2011), the targeting vector used for the
generation of Pax9−/− mice contained an FRT-flanked Neo
expression cassette followed by a Myc-Osr2 cDNA inserted in
intron 2 of Pax9. Pax9+/− mice were derived from crossings with
EIIa (E2a)-Cre mice (Zhou et al., 2011). Studies of Myc-Osr2
expression are facilitated by further crossing of Pax9+/− mice with
FLPeR mice, thus eliminating the Neo cassette and resulting in
expression of Myc-Osr2 (Zhou et al., 2011). Here, we performed
additional experiments to rule out the possibility that WAY-262611
treatments affected transgenic Myc-Osr2 protein and mRNA
expression. Fig. S6A-D shows the absence of a translated protein
product from exogenous Myc-Osr2 in both untreated and treated
Pax9+/− and Pax9−/− palatal shelves. By contrast, Myc-Osr2 is
clearly visible in a section through Pax9+/−;FLP palate and tooth
mesenchyme, where Myc-Osr2 from the transgenic Osr2 allele is
able to be translated (Fig. S6E). In situ hybridization using an Osr2-
specific probe that detects both exogenous and endogenous Osr2
mRNA showed stronger Osr2 signals in Pax9−/− samples (Fig. S6G,
I) as the extra knock-in Osr2 allele was transcribed into mRNA.
However, no significant differences were noted in Osr2 mRNA
expression levels when comparing untreated and treated Pax9+/−
samples (Fig. S6F,H) or untreated and treated Pax9−/− samples (Fig.
S6G,I). Thus, WAY-262611 treatment itself did not affect Osr2
expression and the closure of palatal shelves following Wnt
interventions cannot be attributed to transgenicMyc-Osr2 expression.
Pax9 deficiency lowers cell proliferation in E13.5 posterior palatal
mesenchyme, as seen by the significant reduction in BrdU
incorporation (Zhou et al., 2013). BrdU assays were performed in
WAY-262611-treated embryos at E13.5 and E14.5, stages when
palatal outgrowth is most visible. After treatment with WAY-262611,
cell proliferation was restored to a level that appeared adequate for the
outgrowth of palatal shelves (Fig. 7A-G). The BrdU labeling assay in
posterior palate at E14.5 showed that the ratios of BrdU+ palatal
mesenchymal cells were significantly reduced in Pax9−/− samples
(Fig. 7E,F), confirming previous reports (Zhou et al., 2013). AfterWnt
signaling agonist treatments, the ratios of BrdU+ palatal mesenchymal
cells were consistently restored in Pax9−/− samples at both E13.5 and
E14.5 (Fig. 7B,D) as compared with Pax9+/− tissues (Fig. 7A,C,G).
To better understand whether the closure of Pax9−/− palatal
shelves following Wnt agonist treatment included palatine bone
formation, we compared alkaline phosphatase activity and type I
collagen (Col1a1) mRNA expression in treated and untreated
Pax9+/+ and Pax9−/− maxillary and palatine processes. The robust
levels of enzymatic activity observed in treated Pax9−/− tissues
closely resembled that in Pax9+/+ tissues and showed the onset of
osteogenesis in these areas (Fig. 8A-F). The alkaline phosphatase
activity that marks early osteoblast differentiation was activated in
areas of mesenchymal condensations at osteogenic fronts within
palatal mesenchyme at E15.5 in Pax9+/+ embryos (Fig. 8A,D).
Fig. 3. Genetic reduction of Dkk1 expression
rescues secondary palate clefts in Pax9−/− mice.
(A-C) Representative whole-mount oral views of
palate formation in E18.5 embryos. (A) Normal palate
closure in Pax9+/−Dkk1f/+ embryos. (B) The
phenotype of cleft palate in Pax9−/−Dkk1f/+ embryos
(n=4). (C) Intact palate with disordered rugae in
Pax9−/−Dkk1f/+;Wnt1Cre embryos. n=5. (D-F) H&E
staining of coronal sections. (D) Fusion of the palatal
shelves in an Pax9+/−Dkk1f/+ embryo. (E) Failure of
palatal shelf outgrowth and closure in a Pax9−/−Dkk1f/+
embryo. (F) The cleft defect is reversed genetically in a
Pax9−/−Dkk1f/+;Wnt1Cre embryo. (G-I) Masson’s
trichrome staining of serial sections show the
deposition of connective tissue (blue) within the palatal
shelves of (G) Pax9+/−Dkk1f/+ and (I) Pax9−/−Dkk1f/+;
Wnt1Cre, while only maxillary bone tissue was stained
blue in Pax9−/−Dkk1f/+ (H) embryos. T, tongue;
asterisk indicates cleft palate; arrowheads indicate
intact palate shelves; arrows indicate molars. Scale
bars: 200 µm.
Fig. 4. Controlled delivery schedule for small-molecule Wnt agonists.
WAY-262611 (two timelines) or IIIc3a (one timeline, based on the high rate of
palatal closure achieved with WAY-262611) was intravenously injected
through the tail vein during the indicated periods (blue bars). Arrows indicate
daily injection. See Table 2 for details.
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However, alkaline phosphatase activity was not detected in stunted
Pax9−/− palatal shelves (Fig. 8B,E). After Wnt agonist treatment,
enzymatic activity was restored in the Pax9−/− palate (Fig. 8C,F).
Col1a1, a marker of differentiated osteoblasts, appeared in
osteoblasts in Pax9+/+ palatal mesenchyme. By contrast, Pax9−/−
samples failed to show Col1a1 expression in putative mesenchyme.
After Wnt agonist treatment, Col1a1 expression was restored along
with the osteogenic activity within the palatal shelves (Fig. 8G-X).
Taken together, these data establish that the intravenous delivery
of small-molecule Wnt agonists to pregnant Pax9+/− females within
a critical gestational window is effective in bringing about true
closure of the palatal shelves in Pax9−/− embryos (Figs 5 and 8).
AlthoughWnt signaling was restored in treated palates, Wnt agonist
therapies did not correct the developmental arrest of tooth organs,
parathyroid glands, thymus and hind limb defects in mutants
(Fig. S7), and nor did the Wnt therapy lead to prolonged survival of
treated Pax9−/− neonates, suggesting that the cleft palate was not the
only defect causing Pax9−/− neonate lethality after birth. MRI
imaging showed that Pax9+/− mothers injected with WAY-262611,
along with their wild-type and heterozygous progeny, showed no
toxic effects or tumor development up to 18 months following the
last tail vein injection (data not shown).
DISCUSSION
In these studies, we provide definitive evidence that Pax9 deficiency
alters Wnt activity in palatal shelves and that this upstream
relationship, when genetically restored, leads to rescue of the cleft
palate phenotype in Pax9−/− embryos. Of significance is the high
fidelity correction of palatal defects in Pax9−/− embryos after the
controlled intravenous delivery of small-molecule Dkk inhibitors
(Wnt agonists) to pregnant Pax9+/− mice during a critical
developmental window for palatogenesis. Such interventions
restored Wnt signaling in palatal mesenchyme and specifically
increased cell proliferation within posterior palatal mesenchyme,
where Pax9 and Dkk1/2 have inverse expression patterns. Wnt
activation in Pax9−/− palates led to a true bony closure of palatal
shelves through osteogenesis. Collectively, these data demonstrate that
the Pax9/Wnt pathway is crucial for the formation of the secondary
palate and that restoring this molecular equilibrium in Pax9−/−mice in
utero leads to the complete fusion of palatal shelves.
Pax9-dependent Wnt signaling along the buccal-lingual axis
is important for palate development
Our studies demonstrate that Pax9-dependent Wnt signaling in the
posterior domain of palatal mesenchyme influences growth along
the buccal-lingual axis, thus providing new insights into the
molecular mechanisms underlying Pax9 actions in palatogenesis.
The inverse or complementary patterns of Pax9 and Dkk1/2 gene
expression in posterior mesenchyme suggest that Pax9 modulates
Wnt signaling in this region of the palate. Our unbiased studies of
genome-wide alterations in whole Pax9−/− palatal shelves showed a
significant increase in Dkk1 and Dkk2 expression. Genes involved
in other signaling pathways, such as Msx1 and Bmp4, were also
altered. Since these genes influence signaling events in anterior
palatal mesenchyme this explains why Wnt agonist therapy did not
result in closure of palatal defects in Msx1−/− mice. We also
conclude that Pax9-dependent Wnt signaling through the control
of Dkk1 expression is key for posterior palate formation. Our
expression analyses support the results of studies by Li et al. (2017)
that show the restriction of Axin2 and Ctnnb1 to the posterior
region of the palate and that these genes are downregulated in the
absence of Pax9, while Dkk2 levels increase in posterior palatal
mesenchyme. Notably, the expression levels of selective Wnt
ligands were reduced in the absence of Pax9 and were not
normalized after activation of Wnt signaling. Earlier studies have
Table 2. Secondary palate closure after treatment with Wnt agonists
Treatment Experimental group Timeline Dose (mg/kg) Pax9−/− (n) Palate closure* Cleft palate
WAY-262611 1 E10.5-14.5 12.5 6 6 (2) 0
2 E10.5-14.5 25 12 12 (5) 0
3 E10.5-13.5 12.5 8 3 (1) 5
4 E10.5-13.5 25 9 6 (3) 3
IIIc3a 5 E10.5-14.5 12.5 9 7 (3) 2
6 E10.5-14.5 25 6 5 (3) 1
*The number in parentheses indicates the number of Pax9−/− embryos (n) with small residual fusion defects between the primary and secondary palates.
Fig. 5. Fusion of the secondary palate inPax9−/− embryos after intravenous
delivery of small-molecule Wnt agonists. (A-D) Representative whole-mount
oral views of palatal shelves. (A) In a Pax9+/+ embryo at E18.5, normal palatal
fusionwith parallel rugae arrangement is visible. (B) Cleft in the secondary palate
was a consistent phenotype in control-treated Pax9−/− embryos at E18.5 (n=10).
(C,D) Intravenous delivery of WAY-262611 (n=18) and IIIc3a (n=12) led to the
closure of palatal shelves in the midline. However, rugae appear less organized
compared with Pax9+/+ embryos. R3, ruga 3; arrows indicate the third ruga;
asterisk indicates cleft palate or secondary palate fusion after treatment.
(E-H) H&E staining of coronal sections through E18.5 heads, showing that the
palatal shelveswere fused inPax9+/+mice (E), whereas a cleft palatewas visible
in a mutant littermate (F). Note the arrest in tooth formation at the bud stage
(arrows). Compared with those that received control injections (F), closure of the
palatal shelves was clearly evident in WAY-262611-treated (G) or IIIc3a-treated
(H)Pax9−/−mice.Note that in treatedmice, tooth organs did not advance beyond
the early cap stage (arrows). (I-P) Masson’s trichrome staining of position-
matched sections showing that the deposition of connective tissue (blue) within
the palatal shelves of WAY-262611-treated (K,O) and IIIc3a-treated (L,P) Pax9−/−
mice resembled that in control samples (I,J,M,N). The boxed region in I-L is
enlarged in M-P. T, tongue; arrowheads indicate intact palate shelves; arrows
indicate the first molar; asterisk indicates cleft palate. Scale bars: 200 µm.
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shown that Dkk1 expression can be regulated by Wnt-induced TCF
activation through a negative-feedback mechanism (Niida et al.,
2004). Hence, it will be interesting to explore whether Pax9 directly
regulates the expression of Wnt ligands.
Notably, the role of Pax9 in regulating the Wnt signaling pathway
through its inhibition of Dkk1 suggests that it serves dual
transcriptional functions in palatogenesis. As an activator of Bmp
and Fgf signaling in anterior palatal mesenchyme and as a likely
repressor of Dkk1 in posterior mesenchyme, Pax9 influences
patterning morphogenesis throughout the forming palate. The
literature underscores the role of Pax family members as
transcriptional regulators that act as activators and repressors during
development. For example, Pax6 has dual roles in eye development
(Duncan et al., 1998), as it serves as an activator of the αA-, αB- and
δ1-crystallin genes while repressing expression of the β-crystallin
gene in the lens. Pax4 also acts as a transcriptional repressor in the
pancreas (Fujitani et al., 1999). It is well established that Pax9 is
involved in the formation of pharyngeal organs (thymus, parathyroid)
as well as tooth and palate development. Pax9 activates the Bmp
and Fgf signaling pathways (Mensah et al., 2004) during tooth
development but is strongly synergistic with BF-1 (brain factor 1, also
known as FOXG1) and the potent breast cancer-associated
transcriptional repressor PLU-1 (also known as KDM5B) (Tan
et al., 2003). Hence, the functions of Pax9 in the development of
craniofacial and pharyngeal pouch derivatives are the result of fine-
tuned modulations of its multiple transcriptional properties.
Although it can be argued that relief of Dkk1 inhibition could
overcome reduced Wnt signaling activity at some other point in the
pathway, the rescue of the cleft palate defect in Pax9−/−Dkk1f/+;
Wnt1Cre compound mutant mice, as shown here, suggests that the
functional relationship of Pax9 with Dkk1 is both necessary and
sufficient for palate shelf closure. Li et al. (2017) indicate that
secondary palate clefts are rescued in 14 out of 20 double mutants
that lack Wise (also known as Sostdc1), which encodes another
secreted Wnt ligand-receptor antagonist that also modulates Bmp
signaling. A confounding observation is that, in the absence of
Pax9, expression levels of Wise are downregulated in palatal
shelves. Our studies provide definitive evidence that the role of Pax9
in regulating the Wnt signaling pathway through its inhibition of
Dkk1 is one means by which it exerts modulatory functions in
patterning morphogenesis. Clearly, the relationship with other Wnt
signaling molecules and pathways, such as Bmp and Fgf signaling,
also plays a role in processes that drive palatogenesis.
The correction of Pax9mutant palatal defects with Wnt
agonists underscores the importance of this molecular
pathway in secondary palate formation
The surprising fidelity with which palatal defects are corrected in
Pax9−/− embryos through the controlled intravenous delivery of
Fig. 6.Wnt signaling activity and the expression of downstream targetswere partially restored inPax9−/−palate after treatments. (A-F)Whole-mount lacZ
staining (blue) of Pax9−/−;BAT-Gal mice at E14.0 to assess Wnt signaling activity after Wnt agonist therapies. WAY-262611 and IIIc3a slightly increased Wnt
activity in the posterior palatal region of Pax9+/−;BAT-Galmice (compare Awith B,C). However, a more significant and expanded level of Wnt activity is observed
within posterior palatal shelves of Pax9−/−;BAT-Gal mice (compare D with E,F). Arrows point to the Wnt signaling activity in palate; dashed line indicates the
boundary of palate. (G) The mRNA levels of selected differentially expressed genes were verified by quantitative RT-PCR using E13.5 microdissected control
(CTR) or WAY-26261-treated (WAY) palatal shelves (n=5). Error bars indicate s.e.m. *P<0.01.
Table 3. Differentially expressed genes in Pax9−/− samples with or















Fgf4 11.91 73.41 4.96 152.77 −30.77* 2.40*
Gbx2 9.95 22.39 4.15 27.50 −6.62* 2.40*
Hoxb2 4.50 17.99 1.28 8.15 −6.36* 3.51*
Phox2b 310.88 366.25 40.25 193.65 −4.81* 7.72*
Phox2a 157.04 203.49 22.93 86.78 −3.78* 6.85*
Hand2 177.22 219.69 36.10 127.48 −3.53* 4.91*
Mmp7 6.88 4.59 2.22 5.85 −2.64* 3.10*
Ascl1 109.57 121.37 38.55 92.15 −2.39* 2.84*
Hmx3 22.26 29.60 9.06 16.56 −1.83* 2.46*
Alk 120.52 128.84 70.67 114.27 −1.62* 1.71*
L1cam 981.37 1276.89 634.81 919.99 −1.45 1.55*
Mmp24 50.47 47.89 24.82 31.41 −1.27 2.03*
Gfi1 14.63 11.42 9.02 9.67 0.93 1.62*
Tnnt3 678.95 489.04 431.67 439.72 0.98 1.57*
Ush1c 5.31 9.96 8.50 8.09 1.05 −1.60*
Otop1 3.68 2.00 10.54 9.97 1.06 −2.87*
Ccl2 38.07 73.20 69.29 64.58 1.07 −1.82*
Tmc1 6.88 4.90 11.82 6.11 1.93* −1.72*
Slc17a8 13.17 14.30 29.78 13.21 2.25* −2.26*
Expression levels are shown as normalized counts. *P<0.01 for each
comparison; FC, fold change; −, downregulation; WAY, WAY-262611
treatment; CTR, control treatment.
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Wnt agonists can be explained by the fact that Wnt signaling genes
are potent downstream effectors of Pax9 functions in palatal
mesenchyme. Interestingly, such interventions could not restore the
development of the thymus, parathyroid glands and ultimobranchial
bodies, or correct other defects such as supernumerary preaxial
digits. It is likely that organs, other than the secondary palate, that
are derived from the pharyngeal pouches may require essential
contributions from other downstream effector pathways such as
Bmp, Fgf and Shh. Alternatively, Wnt agonist delivery and dosage
schedules that proved optimal for palatogenesis would have to be
modified to achieve the correction of other organ defects in Pax9−/−
mice.
The interventions with small-molecule Wnt agonists failed to
prolong the survival of Pax9−/− neonates from treated
pregnant dams as they succumb at birth. While earlier studies
have noted that Pax9−/− newborn pups die shortly after birth, most
likely as a consequence of secondary palate clefts (Peters et al.,
1998), our data suggest that systemic alterations caused by the
absence of parathyroids and thymus glands might lead to early
death.
It is intriguing that Wnt agonists when delivered intravenously
during a critical developmental window for odontogenesis only
advanced tooth organs to the early cap stage. In humans, mutations
in PAX9 are mainly associated with congenitally missing posterior
teeth (Goldenberg et al., 2000; Stockton et al., 2000). Pax9 also
influences epithelial-mesenchymal signaling events that drive
murine tooth morphogenesis (Peters et al., 1998; Nakatomi et al.,
2010). Mutations in WNT10A account for the majority of human
tooth agenesis cases (Bohring et al., 2009; van den Boogaard et al.,
2012; Mues et al., 2014) and canonical Wnts are key drivers of
tooth signaling interactions that are likely to be downstream of
Pax9 in dental mesenchyme (O’Connell et al., 2012; Jia et al.,
2016). Pax9 also integrates dental mesenchymal signaling events
that involve Bmp4, Fgf3 or Fgf10 (Peters et al., 1998; Nakatomi
et al., 2010). Hence, combinatorial therapies involving Wnt
agonists and these growth factors might prove more effective in
advancing tooth morphogenesis and should be the focus of future
studies.
We also observed that the intravenous delivery of small-molecule
Wnt agonists failed to rescue cleft defects in any of 50Msx1−/−mice
examined. Msx1 is a partner gene of Pax9 that also plays a role in
palatogenesis and is more dominantly expressed in the anterior zone
of palatal mesenchyme. By contrast, Pax9 and Dkk1/2 are more
restricted to the posterior region. We hypothesize that a
morphogenetic gradient of differential gene expression along the
AP axis controls the patterning and closure of palatal shelves
(Hilliard et al., 2005; Zhou et al., 2013) and that downstream
effector genes other than the Wnts are likely to mediate Msx1
actions in anterior palatal mesenchyme.
Fig. 7. Cell proliferation in the palate of WAY-262611-
treated Pax9−/− mice. Representative images of sections
through the posterior regions of the palate in E13.5 and E14.5
Pax9+/− (A,C,E) and Pax9−/− (B,D,F) embryos with (A-D) or
without (E,F) WAY-262611 treatment. Red signals show the
distribution of BrdU-labeled nuclei. Blue signals show total
nuclei (Hoechst). T, tongue; p, palate shelf. (G) The
percentage of BrdU-labeled cells in the palatal mesenchyme.
n=5. Error bars represent s.d. *P<0.01; ns, not significant.
Fig. 8. The restoration of osteogenesis in WAY-262611-treated Pax9−/−
palatal shelves. (A-F) Detection of alkaline phosphatase activity in the palatal
mesenchyme during palatal bone formation in Pax9+/+ and Pax9−/− embryos
without or with WAY-262611 treatment. Position-matched coronal sections of
E15.5 embryos through the anterior and posterior palates are shown.
(A,D) Alkaline phosphatase activity (blue) was detected in the palate ofPax9+/+
embryos but not in Pax9−/− embryos (B,E). After Wnt agonist treatment,
enzymatic activity was detected in the Pax9−/− palate (C,F). (G-X) Comparison
of expression ofCol1a1mRNA (blue) in the palatal mesenchyme during palatal
bone formation in Pax9+/+ and Pax9−/− embryos without or with WAY-262611
treatment. Position-matched coronal sections of E15.5 (G-L), E16.5 (M-R) and
E18.5 (S-X) embryos through the anterior and posterior palates are shown.
Expression ofCol1a1 was detected within osteogenic zones as early as E15.5
(G,J) and increased from E16.5 (M,P) to E18.5 (S,V) in Pax9+/+ palates. In
Pax9−/− palate, expression ofCol1a1was highly reduced (H,K,N,Q,T,W). After
Wnt agonist treatment, Col1a1 expression was restored in the palate of Pax9−/−
embryos (I,L,O,R,U,X). Arrows point to osteogenic centers of the developing
palatal processes of the maxilla; arrowheads indicate prospective palatal
processes of the palatine bone. n=5 for each assay. Scale bars: 200 µm.
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Clinical implications for the use of small-molecule
replacement therapies for the treatment of developmental
disorders of the craniofacial complex
The involvement of the Wnt–β-catenin signaling pathway in many
developmental processes and in adult tissue homeostasis has
encouraged the development of pharmacological modulators of
this pathway (Clevers and Nusse, 2012; Baron and Kneissel, 2013;
Kahn, 2014). Previously, a small-molecule-based chemical
genetic approach restored the stability and function of GSK3β in
Gsk3bFRB*/FRB* mice such that, after rapamycin treatment, cleft
defects were rescued in 6/9 mutant pups (Liu et al., 2007). New
therapies that block the function of the Wnt antagonist sclerostin
restored bone mass and strength in humans at risk of fractures
(Recker et al., 2015). Several preclinical studies also report that
other therapies targeting Dkk1 inhibition induce bone gain (Baron
and Kneissel, 2013).
Our data indicate that the intravenous administration of
small-molecule Dkk inhibitors increases Wnt signaling in palatal
mesenchyme and enhances cell proliferation, palatal shelf outgrowth
and fusion. Restoration of cell proliferation during a critical
developmental window, when expansion of the cranium can force
shelves apart, appears crucial for palate formation. In humans,
submucosal clefting occurs as commonly as overt cleft palate and is
the result of apposition of overlying soft tissue with a lack of palatal
bone formation (Garcia Velasco et al., 1988). For this reason, it was
important for us to first demonstrate that Wnt agonist therapies
positively affect palate morphogenesis (as shown by increased cell
proliferation) and that this was sufficient for osteogenesis to ensue
within the palatal shelves. Further studies are needed to delineate stage-
specific effects ofWnt agonist therapies and the role of Pax9-dependent
Wnt signaling in palatal shelf growth and bone formation.
Questions naturally arise about how such approaches can be
translated into therapies for human cleft palate disorders. Since Wnt
signaling is key to the development of several organs, activation of
the pathway through exogenous Wnt agonist therapies could lead to
abnormalities in other organ systems. Our histopathologic and MRI
imaging analyses of pregnant Pax9+/− females that received Wnt
agonist injections and surviving Pax9+/+ or Pax9+/− littermates
showed no toxic effects or tumor development up to 18 months
following the last tail vein injection. Hence, small doses of Wnt
agonists that target inhibitors of receptor binding, when delivered in
a controlled manner and during a specific developmental window,
only affect cells such as those in the palatal mesenchyme that have
not reached the threshold levels needed for the hierarchy of Wnt
signaling.
Although ultrasound technologies can diagnose cleft palate
conditions as early as 13 weeks of gestation, small-molecule
therapies delivered in low doses to pregnant mothers are likely to
be fraught with difficulties and will require further experimentation
on risk-to-benefit ratios. Alternate strategies to reduce exposure of the
mother could include delivery into the amniotic fluid, as shown to be
effective for the delivery of recombinant ectodysplasin (Hermes et al.,
2014). Alternatively, early postnatal interventions that utilize the
well-timed local delivery of Wnt agonist small molecules or proteins
during surgical correction procedures might prove effective in
bringing about the timely closure of palatal shelves.
MATERIALS AND METHODS
Animals
All animal procedures were approved by the Institutional Animal Care and
Use Committee (IACUC) at the University of Utah (Protocol #17-02004).
Pax9+/− and Msx1+/− mice were provided by Dr Rulang Jiang (Cincinnati
Children’s Hospital) (Zhou et al., 2011) and Dr Yiping Chen (Tulane
University). Whole heads of E13.5 and E14.5Dkk1Tg107−lacZ embryos were
provided by Dr Ulrich Rüther (Heinrich-Heine University) (Lieven et al.,
2010). BAT-Gal mice for studies on Wnt activity (Maretto et al., 2003) and
FLP male mice for the generation of positive control Myc-Osr2 (JAX
016226) were purchased from Jackson Laboratories. Pax9+/−, Msx1+/− and
BAT-Gal mice were maintained in a C57BL/6 background. Females at 2-8
months of age were used for intercross matings and adult mice, over
18 months of age, were used for the histopathologic and magnetic resonance
imaging (MRI) analysis of potential side effects and toxicity following
treatments. We were diligent in including litter-matched controls that were
subject to the same Wnt agonist therapy in utero. However, since some
litters failed to yield Pax9+/+ progeny, Pax9+/− littermates were used instead
as it is well documented that Pax9 haploinsufficiency does not compromise
the development or function of any organ system (Peters et al., 1998; Zhou
et al., 2011).
Pax9−/−Dkk1f/+;Wnt1Cre compound mutant mice were generated through
serial matings. Pax9+/−mice were first mated withDkk1f/+ mice [EM: 09872
from the European Mouse Mutant Archive (EMMA) repository] to generate
Pax9+/−Dkk1f/+ progeny. We next mated Pax9+/−Dkk1f/+ with Wnt1-Cre
(JAX 022501, Jackson Laboratory) to generate Pax9+/−Dkk1f/+;Wnt1Cre
males. Pax9−/−Dkk1f/+;Wnt1Cre embryos were then obtained from the
mating of Pax9+/−Dkk1f/+;Wnt1Cre males with Pax9+/−Dkk1f/+ females.
Palatal dissections, RNASeq and quantitative RT-PCR
The embryos were harvested at E13.5 and heads collected in cold PBS. After
the lower jaw and brain were removed under a dissecting microscope, the
status of the palatal shelves was evaluated. Palatal tissues were carefully
dissected using fine forceps, quickly frozen in liquid nitrogen and stored
individually at −80°C for total RNA extraction (Zhou et al., 2013; Kim
et al., 2017).
Whole-transcriptome profiling of developing palatal shelves was
performed by RNASeq as previously described (Jia et al., 2013).
Sequenced reads were mapped to the reference mouse genome (mm10)
using NovoAlign (v2.08.03, Novocraft). Read counts were generated using
the USeq (http://useq.sourceforge.net) Defined Region Differential Seq
application and normalized counts were used in DESeq2 (Bioconductor) to
measure differential expression. The RNASeq raw data are available at GEO
under accession numbers GSE89603 and GSE101825. The candidate genes
were screened from a comparison of five sets of data as follows: first, the
normalized counts were cut-off at 10 in at least one of the samples, then the
fold change was chosen at 1.5-fold or higher and P<0.01 from the Audic-
Claverie test with Benjamini-Hochberg false-discovery rate (FDR) multiple
testing correction; next, the gene list was sorted by P-value and lists of genes
were submitted to DAVID (https://david.ncifcrf.gov) or ToppGene (https://
toppgene.cchmc.org) for functional enrichment analysis.
Palatal shelves were microdissected from E13.5 embryos. After
genotyping, total RNA was extracted from individual samples using the
RNeasy Micro Kit (Qiagen). First-strand cDNA was synthesized using the
SuperScript First-Strand Synthesis System IV (Thermo Fisher Scientific).
Quantitative reverse-transcription PCR (RT-PCR) was performed in a
StepOnePlus Real-Time PCR System (Applied Biosystems) using the
SYBR GreenER qPCR Supermix (Thermo Fisher Scientific). A list of gene-
specific primers is provided in Table S1. For each sample, the relative levels
of target mRNAs were normalized to Gapdh using the standard curve
method. Five sets of replicates were analyzed for each gene.
Delivery of small-molecule Wnt pathway agonists
Two small-molecule agonists (Millipore) were used to treat timed pregnant
female mice. WAY-262611, {1-[4-(naphthalen-2-yl)pyrimidin-2-yl]
piperidin-4-yl}methanamine, is a 2-aminopyrimidine compound (Fig. S2A)
that antagonizes the effect of Dkk1 by preventing the formation of the Dkk1-
LRP5-Kr2 complex. It has a half-life (t1/2) of 6-8 h in plasma (Pelletier et al.,
2009) and specifically inhibits Dkk1 at EC50=0.63 µM, based on a TCF-
luciferase assay. IIIc3a, 9-carboxy-3-(dimethyliminio)-6,7-dihydroxy-10-
methyl-3H-phenoxazin-10-ium iodide, is an enhanced in-solution stable
gallocyanine analog (Fig. S2B) that disrupts the interaction of LRP5/6 with
Dkk1, Dkk2 and Dkk4 in a competitive manner at EC50=5 µM in a
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LEF-luciferase assay using NIH3T3 cells (Li et al., 2012). Stock solutions of
WAY-262611 and IIIc3a were prepared at 25 mg/ml in DMSO. Dilutions at
12.5 and 25 mg/kg per mouse body weight were prepared prior to injection
into the tail vein as previously described (Kowalczyk et al., 2011). Control
treatments consisted of tail vein injections of 10% DMSO in PBS. WAY-
262611 or IIIc3a was delivered separately on a daily basis from E10.5 to
E14.5, while an additional group of mice received WAY-262611 treatments
from E10.5 to E13.5 as detailed in Table 2. Mice were closely monitored for
any discomfort or side effects.
Microscopic evaluations and in situ hybridizations
Embryos retrieved from treated and untreated litters were immediately fixed in
4% paraformaldehyde (PFA) overnight. Paraffin sections (7 μm thick) were
prepared and stained with Hematoxylin and Eosin (H&E) for microscopic
evaluation. In situ hybridizations were performed using digoxigenin-labeled
RNA probes to Dkk1, Dkk2, Pax9, Osr2 and Col1a1 as described previously
(D’Souza et al., 1993; Zhang et al., 1999). 1 µg/ml antisense RNA probe was
loaded on each section and anti-digoxigenin-AP antibody (11093274910,
Roche; 1:1000) was used to detect the labeled probe. BM-purple
(11442074001, Roche) was used for color development. Comparable
images were captured on a digital microscope (EVOS). For whole-mount
in situ hybridizations, 2 µg/ml antisense RNA probe was loaded on each
sample and the anti-digoxigenin-AP antibody (1:2000) used to detect the
labeled probe. NTMT buffer with 4.5 μl/ml nitroblue tetrazolium (NBT) and
3.5 μl/ml 5-bromo-4-chloro-3-indolyl phosphate (BCIP) was used for color
development. Adding both NBT and BCIP helped enhance the development
of the reaction. For each assay, at least five replicates were performed.
Gross morphological examinations, histopathology and MRI
analyses
All mouse embryos, neonates and adults were first evaluated through full-
body visual examination. Whole embryos were fixed in 10% neutral-buffered
formalin, and 7 μm-thick transverse paraffin sections were stained with H&E
for microscopic evaluation. Pax9−/− embryos from treated and control litters
were easily identifiable by the supernumerary hind limb digit. However,
genotyping was performed on all animals. Adult mice were anaesthetized
with isoflurane and fixed by whole-body perfusion prior to magnetic
resonance imaging (MRI) that was performed using a 7 Tesla Bruker BioSpec
MRI scanner under the following parameters: a T2 weighted RARE scan was
acquired using a 7.2 cm diameter quadrature radiofrequency transmitter-
receiver (Bruker Biospec), with 125 µm isotropic resolution, echo train length
of 4, matrix size of 768×256×256 and TE/TR=41/1200 ms on a Bruker
Biospec 70/30 instrument (Bruker Biospin).
Histochemical and immunofluorescent staining procedures
For whole-mount lacZ staining, embryos were fixed in 1% PFA then treated
as previously described (Lan et al., 2004). In addition, serial coronal
sections were stained with Masson’s trichrome (Chen et al., 2009) to
evaluate connective tissue deposition. For alkaline phosphatase (AP)
staining, embryos were fixed in 4% PFA overnight. The frozen sections
were incubated in NTMT buffer (100 mMNaCl, 100 mM Tris-HCl pH 9.5,
50 mM MgCl2, 0.1% Tween 20) containing 4.5 μl/ml NBT and 3.5 μl/ml
BCIP for 20 min at room temperature (Baek et al., 2011). Comparable
images were taken with a digital microscope (EVOS) or a stereomicroscope
(Zeiss Stemi 508). For each assay, at least five replicates were used to
establish reproducibility of results.
For immunofluorescent staining, embryos were fixed in 4% PFA overnight
at 4°C and processed for paraffin sections (7 µm). Indirect immunofluorescent
staining was performed as described (Zhou et al., 2011). After blocking with
PBS containing 10% goat serum, 2% BSA and 0.1% Tween 20, overnight
incubation with monoclonal anti-Myc antibody (Millipore, 05-724; 1:100 in
blocking solution) was carried out at 4°C. The secondary antibody used was
goat anti-mouse IgG, Alexa Fluor 594 (Thermo Fisher Scientific, R37121;
1:1000 in blocking solution).
BrdU labeling and cell proliferation assay
As reported, palatal cell proliferation is decreased in Pax9−/− embryos as
early as E13.5 (Zhou et al., 2013) and contributes to the failure of shelf
outgrowth. Daily delivery of WAY-262611 from E10.5 to E14.5 (5 days)
resulted in 100% palate closure in Pax9−/− embryos, whereas the incidence
of palatal shelf fusion was reduced when drug delivery was stopped a day
earlier at E13.5. Hence, we analyzed E13.5 palatal shelves along with E14.5
palatal shelves to assess the effects of Wnt agonist therapy on cell
proliferation at a critical phase of palatogenesis.
Timed pregnant female micewere injected once intraperitoneally at E13.5
and E14.5 with BrdU Labeling Reagent (Roche; 15 μl/g body weight).
Embryos were harvested 2 h later. Paraffin sections (7 µm) were prepared in
the coronal plane and spanning the entire posterior region of the palatal
shelves. After rehydration, proteinase K digestion was followed by HCl
treatment and incubation in a blocking solution (2% BSA, 10% goat serum,
0.1% Tween 20 in PBS). Samples were treated with Alexa Fluor 594-
conjugated anti-BrdU antibody (Thermo Fisher Scientific, B35132; 1:50 in
blocking solution) overnight. After counterstaining with Hoechst, images
were obtained from 20 sections per tissue sample using a Nikon A1R
confocal microscope and analyzed with Imaris software (Bitplane). The cell
proliferation data were recorded and analyzed from five independent control
and mutant littermate pairs.
Whole palate shelf organ culture
The WAY-262611-treated palates were dissected on ice by removing the
lower jaw and brain, and samples with residual fusion defects were marked
and cultured as previously described (Almaidhan et al., 2014). Pax9+/− and
untreated Pax9−/− embryos were cultured as controls. The dissected E18.5
palate shelves were placed in 2 ml medium [CO2 Independent Medium
(Thermo Fisher Scientific, 18045-088), 20% FBS, 1× antimycotic-antibiotic
(Thermo Fisher Scientific, 15240-096)]. Culture tubes were rotated 12 rpm at
an angle of 20° in a 37°C incubator for 3 days with daily changes of medium.
After images were taken with a stereomicroscope, tissues were fixed and
embedded for histologic analyses. At least five replicates of each treatment
and genotype were utilized for culture experiments.
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Lieven, O., Knobloch, J. and Rüther, U. (2010). The regulation of Dkk1 expression
during embryonic development. Dev. Biol. 340, 256-268.
Liu, K. J., Arron, J. R., Stankunas, K., Crabtree, G. R. and Longaker, M. T.
(2007). Chemical rescue of cleft palate and midline defects in conditional GSK-
3beta mice. Nature 446, 79-82.
Maretto, S., Cordenonsi, M., Dupont, S., Braghetta, P., Broccoli, V., Hassan,
A. B., Volpin, D., Bressan, G. M. and Piccolo, S. (2003). Mapping Wnt/beta-
catenin signaling during mouse development and in colorectal tumors. Proc. Natl.
Acad. Sci. USA 100, 3299-3304.
Mensah, J. K., Ogawa, T., Kapadia, H., Cavender, A. C. and D’Souza, R. N.
(2004). Functional analysis of a mutation in PAX9 associated with familial tooth
agenesis in humans. J. Biol. Chem. 279, 5924-5933.
Mossey, P. A., Little, J., Munger, R. G., Dixon, M. J. and Shaw,W. C. (2009). Cleft
lip and palate. Lancet 374, 1773-1785.
Mues, G., Bonds, J., Xiang, L., Vieira, A. R., Seymen, F., Klein, O. and D’Souza,
R. N. (2014). The WNT10A gene in ectodermal dysplasias and selective tooth
agenesis. Am. J. Med. Genet. A 164A, 2455-2460.
Nakatomi, M., Wang, X.-P., Key, D., Lund, J. J., Turbe-Doan, A., Kist, R., Aw, A.,
Chen, Y., Maas, R. L. and Peters, H. (2010). Genetic interactions between Pax9
and Msx1 regulate lip development and several stages of tooth morphogenesis.
Dev. Biol. 340, 438-449.
Niida, A., Hiroko, T., Kasai, M., Furukawa, Y., Nakamura, Y., Suzuki, Y., Sugano,
S. and Akiyama, T. (2004). DKK1, a negative regulator of Wnt signaling, is a
target of the beta-catenin/TCF pathway. Oncogene 23, 8520-8526.
O’Connell, D. J., Ho, J. W. K., Mammoto, T., Turbe-Doan, A., O’Connell, J. T.,
Haseley, P. S., Koo, S., Kamiya, N., Ingber, D. E., Park, P. J. et al. (2012). A
Wnt-bmp feedback circuit controls intertissue signaling dynamics in tooth
organogenesis. Sci. Signal. 5, ra4.
Pauws, E., Hoshino, A., Bentley, L., Prajapati, S., Keller, C., Hammond, P.,
Martinez-Barbera, J.-P., Moore, G. E. and Stanier, P. (2009). Tbx22null mice
have a submucous cleft palate due to reduced palatal bone formation and also
display ankyloglossia and choanal atresia phenotypes. Hum. Mol. Genet. 18,
4171-4179.
Pelletier, J. C., Lundquist, J. T., Gilbert, A. M., Alon, N., Bex, F. J., Bhat, B. M.,
Bursavich, M. G., Coleburn, V. E., Felix, L. A., Green, D. M. et al. (2009). (1-(4-
(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: a wingless beta-
catenin agonist that increases bone formation rate. J. Med. Chem. 52, 6962-6965.
Peters, H., Neubuser, A., Kratochwil, K. and Balling, R. (1998). Pax9-deficient
mice lack pharyngeal pouch derivatives and teeth and exhibit craniofacial and limb
abnormalities. Genes Dev. 12, 2735-2747.
Recker, R. R., Benson, C. T., Matsumoto, T., Bolognese, M. A., Robins, D. A.,
Alam, J., Chiang, A. Y., Hu, L., Krege, J. H., Sowa, H. et al. (2015). A
randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin
antibody, in postmenopausal women with low bone mineral density. J. Bone
Miner. Res. 30, 216-224.
Satokata, I. and Maas, R. (1994). Msx1 deficient mice exhibit cleft palate and
abnormalities of craniofacial and tooth development. Nat. Genet. 6, 348-356.
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